Clinical Trial Detail

NCT ID NCT02584634
Title Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Avelumab

Lorlatinib

Age Groups: adult

No variant requirements are available.